The Economic Burden of Thromboembolic Events Among Patients with Immune-Mediated Diseases

被引:1
作者
Setyawan, Juliana [1 ]
Billmyer, Emma [2 ]
Mu, Fan [2 ]
Yarur, Andres [3 ]
Zichlin, Miriam L. [2 ]
Yang, Hongbo [2 ]
Downes, Nathaniel [2 ]
Azimi, Nassir [4 ]
Strand, Vibeke [5 ]
机构
[1] Arena Pharmaceut Inc, San Diego, CA USA
[2] Anal Grp Inc, 111 Huntington Ave,14th Floor, Boston, MA 02199 USA
[3] Med Coll Wisconsin, Div Gastroenterol & Hepatol, Milwaukee, WI 53226 USA
[4] Sharp Grossmt Hosp, La Mesa, CA USA
[5] Stanford Univ, Sch Med, Div Immunol & Rheumatol, Palo Alto, CA 94304 USA
关键词
Cost; Deep vein thrombosis; Economic burden; Immune-mediated diseases; Ischemic stroke; Myocardial infarction; Pulmonary embolism; Thromboembolic events; DEEP-VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; RISK-FACTORS;
D O I
10.1007/s12325-021-02004-1
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Introduction Thromboembolic events (TEs) are associated with considerable costs. However, there is a paucity of evidence quantifying the economic burden associated with TEs among patients with immune-mediated diseases (IMDs). Methods This retrospective cohort study used the IBM MarketScan(R) Commercial and Medicare Supplemental Claims databases (2014-2018). Commercially insured adults with IMDs were classified into two cohorts based on diagnosis of TEs (deep vein thrombosis, pulmonary embolism, ischemic stroke, myocardial infarction). Patients in the TE cohort were matched on type of IMD, age, sex, and year of diagnosis to patients in the no TE cohort. In the TE cohort, the index date was the date of first TE following first IMD diagnosis. In the no TE cohort, the index date was assigned so the duration from first IMD diagnosis to index date matched the duration for the corresponding patient in the TE cohort. All-cause total healthcare costs were compared between cohorts in the 30-day and 1-year periods following the index date (inclusive). Unadjusted comparisons were conducted using Wilcoxon signed-rank tests. Adjusted results were estimated using generalized estimating equations with robust sandwich estimator. Results Overall, 9681 matched patients were included in each cohort (mean age 61.1 years; 63.7% female). The TE cohort had higher proportions of comorbidities than the no TE cohort (Charlson Comorbidity Index [1.5 vs. 0.9]; p < 0.0001). Adjusted all-cause total healthcare costs were significantly greater in the TE cohort versus no TE cohort in the 30-day and 1-year periods following the index date (cost difference: 30-day, $17,574; 1-year, $36,459; both p < 0.0001) and were driven by inpatient costs (cost difference: 30-day, $14,864; 1-year, $23,360; both p < 0.0001). TE-related healthcare costs were $15,955 and $20,239 in the 30-day and 1-year periods, respectively. Conclusion Among patients with IMDs, TEs are associated with substantial economic burden within 30-days and 1-year following the event.
引用
收藏
页码:767 / 778
页数:12
相关论文
共 17 条
  • [1] AARDA Inc, AUT DIS LIST
  • [2] Changing epidemiology of immune-mediated inflammatory diseases in immigrants: A systematic review of population-based studies
    Agrawal, Manasi
    Shah, Shailja
    Patel, Anish
    Pinotti, Rachel
    Colombel, Jean-Frederic
    Burisch, Johan
    [J]. JOURNAL OF AUTOIMMUNITY, 2019, 105
  • [3] Risk factors for venous thromboembolism in hospitalized patients with acute medical illness - Analysis of the MEDENOX study
    Alikhan, R
    Cohen, AT
    Combe, S
    Samama, MM
    Desjardins, L
    Eldor, A
    Janbon, C
    Leizorovicz, A
    Olsson, CG
    Turpie, AGG
    [J]. ARCHIVES OF INTERNAL MEDICINE, 2004, 164 (09) : 963 - 968
  • [4] All-cause unplanned readmissions in the United States: insights from the Nationwide Readmission Database
    Amritphale, Amod
    Fonarow, Gregg C.
    Amritphale, Nupur
    Omar, Bassam
    Crook, Errol D.
    [J]. INTERNAL MEDICINE JOURNAL, 2023, 53 (02) : 262 - 270
  • [5] Epidemiology of Immune-Mediated Inflammatory Diseases: Incidence, Prevalence, Natural History, and Comorbidities
    El-Gabalawy, Hani
    Guenther, Lyn C.
    Bernstein, Charles N.
    [J]. JOURNAL OF RHEUMATOLOGY, 2010, 37 : 2 - 10
  • [6] Assessing the risk of recurrent venous thromboembolism - a practical approach
    Fahrni, Jennifer
    Husmann, Marc
    Gretener, Silvia B.
    Keo, Hong H.
    [J]. VASCULAR HEALTH AND RISK MANAGEMENT, 2015, 11 : 451 - 459
  • [7] Inflammation and plaque vulnerability
    Hansson, G. K.
    Libby, P.
    Tabas, I.
    [J]. JOURNAL OF INTERNAL MEDICINE, 2015, 278 (05) : 483 - 493
  • [8] The risk of recurrent VTE and major bleeding in a commercially-insured population of cancer patients treated with anticoagulation
    Khorana, Alok A.
    McCrae, Keith
    Milentijevic, Dejan
    McCormick, Nora
    Laliberte, Francois
    Crivera, Concetta
    Lefebvre, Patrick
    Lejeune, Dominique
    Rozjabek, Heather
    Schein, Jeff
    Streiff, Michael B.
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 (02) : E58 - E61
  • [9] Systemic Lupus Erythematosus Is Associated With a High Risk of Venous Thromboembolism in Hospitalized Patients Leading to Poor Outcomes and a Higher Cost: Results From Nationwide Inpatient Sample Database 2003-2011
    Kishore, Shweta
    Jatwani, Shraddha
    Malhotra, Bharat
    Lirette, Seth T.
    Mittal, Varun
    Majithia, Vikas
    [J]. ACR OPEN RHEUMATOLOGY, 2019, 1 (03) : 194 - 200
  • [10] The humanistic and economic burden of venous thromboembolism in cancer patients: a systematic review
    Kourlaba, Georgia
    Relakis, John
    Mylonas, Charalambos
    Kapaki, Vasiliki
    Kontodimas, Stathis
    Holm, Majbrit V.
    Maniadakis, Nikos
    [J]. BLOOD COAGULATION & FIBRINOLYSIS, 2015, 26 (01) : 13 - 31